Latest Dermatology News

Page 4 of 6
Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.
Victor Sage
Victor Sage
16 Oct 2025
Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.
Victor Sage
Victor Sage
16 Oct 2025
CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.
Ada Torres
Ada Torres
19 Sept 2025
Botanix Pharmaceuticals’ ECCLOCK® gel, a treatment for excessive sweating, has secured regulatory approval in South Korea, paving the way for a commercial launch in early 2026.
Ada Torres
Ada Torres
5 Sept 2025
Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.
Ada Torres
Ada Torres
29 Aug 2025
Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.
Ada Torres
Ada Torres
29 Aug 2025
Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.
Ada Torres
Ada Torres
29 Aug 2025
Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.
Ada Torres
Ada Torres
29 Aug 2025
Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.
Ada Torres
Ada Torres
29 Aug 2025
Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.
Victor Sage
Victor Sage
29 Aug 2025
Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.
Ada Torres
Ada Torres
28 Aug 2025
Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.
Ada Torres
Ada Torres
28 Aug 2025

Browse the archive

Full archive